IRMD Q4 2025: 17% Revenue Surge Anchored by 3870 Pump Replacement Wave
IRadimed’s 18th straight record quarter underscores a pivotal inflection: legacy pump replacement is now the primary growth engine, with the 3870 launch set to escalate revenue velocity through 2026. Management’s detailed pipeline visibility and early customer enthusiasm for the 3870 system signal a multi-year runway, but execution on inventory transition and international regulatory clearance will determine the pace and sustainability of this next phase. Investors should monitor the ramp in replacement sales and the impact of higher ASPs as the business targets a $100M+ run rate.
Summary
- Replacement Cycle Drives Next Leg: 3870 pump rollout targets thousands of aging units, cementing multi-year runway.
- Margin Resilience Holds Amid Transition: Gross margin steadiness and cash generation support continued investment.
- International Expansion in Sight: European and Japanese approvals could unlock new growth vectors by late 2026.
Business Overview
IRadimed (IRMD) designs and manufactures magnetic resonance (MR) compatible medical devices, specializing in infusion pump systems and patient monitoring equipment for use in MRI environments. Revenue is primarily generated from sales of MR-compatible IV infusion pumps, patient vital signs monitors, disposable accessories, and ferromagnetic detection systems. The company’s business is divided into pump systems, monitoring systems, disposables, and detection products, with a heavy focus on the U.S. hospital market, which comprised over 80% of revenue in 2025.
Performance Analysis
IRadimed delivered its 18th consecutive quarter of record revenue, with Q4 2025 sales up 17% year-over-year, led by robust demand across all major product lines. The MRI-compatible IV infusion pump segment contributed the largest share, supported by strong replacement activity for legacy pumps. Patient monitoring systems and disposables also posted healthy gains, reflecting increased utilization and procedure volumes.
Gross margins remained resilient at 75% for the quarter and 77% for the year, indicating disciplined pricing and cost control despite the ramp-up of new product inventory. Operating expenses grew modestly, primarily to support the ongoing launch of the 3870 pump and expanded clinical support. Free cash flow was solid, underpinned by strong profitability and working capital discipline, even as the company invested in new facility capacity and inventory buildup ahead of the 3870 launch.
- Pump Replacement Cycle Accelerates: Legacy 3860 system replacement orders drove a double-digit pump revenue increase, with thousands of units still to be replaced.
- Disposables Utilization Outpaces Capital Sales: 18% growth in disposables signals higher device usage and recurring revenue momentum.
- International Contribution Remains Modest: U.S. sales dominate, but regulatory progress in Europe and Japan could diversify the revenue base in 2026 and beyond.
The combination of a large installed base, high-margin consumables, and a visible replacement pipeline positions IRadimed for continued growth, but execution on the 3870 transition and scaling of international markets will be critical watchpoints.
Executive Commentary
"Allow me now to recap the expectations for the new 3870 MR IV pump. Recall that in positioning this new product and its pricing, we anticipate 3870 pump deal ASP will increase 10% to 14%. And yes, the 3870 design is much... we fully expect to penetrate the greenfield opportunities more effectively and also increase utilization among existing customers who may currently only use their older pumps sporadically. But to be very clear, the most significant increase comes from the large replacement opportunity, which is the number one driver we see and will deliver a significant step change in revenue."
Roger Sussi, President and Chief Executive Officer
"I think that initially in the early part of the year, the first half, it'll probably be kind of in line with where we have been. But we anticipate that as we, you know, get into the second half of the year on those higher volumes, which we certainly are looking for, along with, as Roger pointed out, what we're looking for is the higher ASP as well, that we would think that we could, you know, certainly trend a little bit higher in the second half of the year."
Jack Glenn, Chief Financial Officer
Strategic Positioning
1. Replacement-Driven Revenue Model
IRadimed’s business model is pivoting from new installs to a high-visibility replacement cycle, with over 6,400 legacy pump channels in the U.S. alone eligible for upgrade. Management targets replacing 2,000+ channels annually, aiming for a $50 million pump revenue run rate, with additional upside from disposables and maintenance.
2. Premium Pricing and Utilization Upside
The new 3870 pump is expected to command a 10% to 14% higher average selling price (ASP) than its predecessor, while improved usability is designed to drive higher utilization per customer. This dual lever of price and usage supports both top-line and margin expansion.
3. Operational Transition and Inventory Management
With the 3870 launch, IRadimed faces a complex inventory and production transition, balancing the wind-down of 3860 pump inventory with a ramp in 3870 manufacturing. Management is closely monitoring backlog and inventory to avoid disruption during the handoff period, particularly in Q2 2026.
4. International Regulatory Expansion
Regulatory submissions for the 3870 pump in Europe (CE mark) and Japan are on track for late 2026 and summer 2027, respectively. Successful clearance would provide access to new markets and diversify revenue sources, but timelines remain subject to regulatory unpredictability.
5. R&D Pipeline and Product Roadmap
The company has already initiated development on a next-generation MRI monitor, aiming for a 2028 launch. This signals ongoing commitment to product innovation and a multi-year growth horizon beyond the current replacement cycle.
Key Considerations
This quarter marks a strategic inflection, as IRadimed transitions from legacy pump growth to a replacement-centric model with higher ASPs and recurring consumable revenue. The successful launch and scaling of the 3870 system will determine whether the company can sustain its record-setting momentum.
Key Considerations:
- Replacement Opportunity Scale: The majority of legacy pumps are still in the field, providing a multi-year revenue backlog if execution remains strong.
- Gross Margin Durability: Management expects margins to remain stable or improve as 3870 volumes ramp, but subscale production in early 2026 could create temporary pressure.
- International Timing Uncertainty: Regulatory approval in Europe and Japan is not expected until late 2026 or summer 2027, delaying meaningful overseas growth.
- Consumable Growth Leverage: Higher device utilization with the 3870 could drive outsized growth in high-margin disposables over time.
- Facility and Capacity Readiness: New Orlando facility expansion supports volume growth, but operational execution will be tested during the transition.
Risks
Execution risk looms largest as IRadimed navigates the switchover from the 3860 to 3870 platform, with potential for inventory imbalances or production hiccups. Delays in international regulatory approval could postpone geographic diversification. Competitive entry, hospital capital spending cycles, and unforeseen regulatory or quality issues remain persistent industry risks that could impact growth trajectory or margin structure.
Forward Outlook
For Q1 and Q2 2026, IRadimed expects:
- Stable revenue in the first half, driven by MRI monitoring and 3860 pump backlog
- Initial 3870 shipments of 100 to 130 pump channels beginning in April
For full-year 2026, management targets:
- Approaching a $100 million annual revenue run rate as 3870 replacement ramps
Management highlighted several factors that will shape 2026 results:
- Booking strength for 3870 expected to build through Q2 and accelerate in the second half
- Gross margins anticipated to improve as 3870 volumes scale and ASPs rise
Takeaways
IRadimed is entering a new phase of durable, replacement-driven growth, with the 3870 launch expanding both revenue visibility and margin potential. Execution on inventory, customer conversion, and international expansion will define the pace and duration of this next cycle.
- Replacement-Driven Runway: Thousands of legacy pumps remain to be replaced, supporting multi-year revenue growth and higher ASPs.
- Margin and Cash Flow Foundation: Gross margin resilience and disciplined spending provide financial flexibility for continued investment and R&D innovation.
- Watch International and Consumables: Progress on regulatory milestones and sustained growth in disposables will be key signals for long-term upside.
Conclusion
IRadimed’s Q4 2025 results confirm a high-visibility growth inflection, as the 3870 pump replacement wave takes center stage. With robust financials and a clear product roadmap, the company is well positioned, but the coming quarters will test its operational agility and ability to convert pipeline into durable revenue streams.
Industry Read-Through
IRadimed’s results highlight the power of installed base replacement cycles in medtech, especially where regulatory and workflow barriers protect pricing and margin. The company’s experience suggests that product refreshes tied to meaningful usability improvements can unlock both replacement and utilization tailwinds, fueling growth in both capital and recurring revenue streams. For other device makers, the importance of consumables attachment, proactive inventory management during transitions, and regulatory diversification are key lessons. The delayed international ramp also underscores the long lead times and complexity of global medtech expansion, a factor for all sector participants targeting non-U.S. growth.